Elite Pharmaceuticals, Inc. (ELTP) 股票表現
查看Elite Pharmaceuticals, Inc.的財務表現,包括市值、價格變動百分比、本益比,以及歷史和當前股價。
前收盤價0.23
52週高點0.69
打開0.23
52週低點0.21
資金流向6.53%
本益比4.59%
T/O0.00b
市淨率2.35%
離職率0.09%
市值1.91b
股息0
總股數10.74b
股息殖利率0%
批量大小1
Elite Pharmaceuticals, Inc.公司簡介
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products. Elite specializes in oral sustained and controlled release drug products which have high barriers to entry. Elite owns generic products which have been licensed to TAGI Pharma, Epic Pharma, Dr. Reddyâs Laboratories, and Glenmark Pharmaceuticals, Inc., USA. Elite currently has eight commercial products being sold, six products filed with the FDA, additional approved products pending manufacturing site transfer and the NDA filing for SequestOxâ¢. Eliteâs pipeline products include abuse-deterrent opioids which utilize the Companyâs patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain. These formulations are intended to address two major limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. Learn more at www.elitepharma.com.